Current therapeutic interventions in the glycation pathway: evidence from clinical studies
出版年份 2012 全文链接
标题
Current therapeutic interventions in the glycation pathway: evidence from clinical studies
作者
关键词
-
出版物
DIABETES OBESITY & METABOLISM
Volume 15, Issue 8, Pages 677-689
出版商
Wiley
发表日期
2012-12-27
DOI
10.1111/dom.12058
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Chelation: A Fundamental Mechanism of Action of AGE Inhibitors, AGE Breakers, and Other Inhibitors of Diabetes Complications
- (2012) R. Nagai et al. DIABETES
- Effect of Benfotiamine on Advanced Glycation Endproducts and Markers of Endothelial Dysfunction and Inflammation in Diabetic Nephropathy
- (2012) Alaa Alkhalaf et al. PLoS One
- Effect of Sevelamer and Calcium-Based Phosphate Binders on Coronary Artery Calcification and Accumulation of Circulating Advanced Glycation End Products in Hemodialysis Patients
- (2011) Takatoshi Kakuta et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria
- (2011) Naila Rabbani et al. AMINO ACIDS
- Calcium Channel Blocker Inhibition of AGE and RAGE Axis Limits Renal Injury in Nondiabetic Patients With Stage I or II Chronic Kidney Disease
- (2011) Tsukasa Nakamura et al. CLINICAL CARDIOLOGY
- Restriction of Advanced Glycation End Products Improves Insulin Resistance in Human Type 2 Diabetes: Potential role of AGER1 and SIRT1
- (2011) J. Uribarri et al. DIABETES CARE
- Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes
- (2011) Lian Engelen et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure
- (2011) Jasper W.L. Hartog et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effects of Metformin and Pioglitazone on Serum Pentosidine Levels in Type 2 Diabetes Mellitus
- (2011) I. Kanazawa et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Pyridorin in Type 2 Diabetic Nephropathy
- (2011) E. J. Lewis et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Irbesartan treatment does not influence plasma levels of the advanced glycation end products N (1-carboxymethyl)lysine and N (1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial
- (2011) L. Engelen et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Potential New Therapeutic Agents for Diabetic Kidney Disease
- (2010) Faruk Turgut et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Modulation of Advanced Glycation End Products by Candesartan in Patients with Diabetic Kidney Disease-A Dose-Response Relationship Study
- (2010) Sandeep A Saha et al. AMERICAN JOURNAL OF THERAPEUTICS
- Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics
- (2010) Casper G. Schalkwijk et al. AMINO ACIDS
- Increased Glycation and Oxidative Damage to Apolipoprotein B100 of LDL Cholesterol in Patients With Type 2 Diabetes and Effect of Metformin
- (2010) N. Rabbani et al. DIABETES
- A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy
- (2010) A. Alkhalaf et al. DIABETES CARE
- Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes
- (2010) N. Karachalias et al. DIABETOLOGIA
- Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH
- (2010) Yuki Kimura et al. JOURNAL OF GASTROENTEROLOGY
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
- (2010) The Emerging Risk Factors Collaboration LANCET
- A New Perspective on Therapeutic Inhibition of Advanced Glycation in Diabetic Microvascular Complications: Common Downstream Endpoints Achieved Through Disparate Therapeutic Approaches?
- (2009) Karly C. Sourris et al. AMERICAN JOURNAL OF NEPHROLOGY
- Short-Term Low Calorie Diet Intervention Reduces Serum Advanced Glycation End Products in Healthy Overweight or Obese Adults
- (2009) Alejandro Gugliucci et al. ANNALS OF NUTRITION AND METABOLISM
- Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis
- (2009) Hiroshi Mitsuhashi et al. ATHEROSCLEROSIS
- Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes
- (2009) H.L. Tam et al. ATHEROSCLEROSIS
- Measurement of pentosidine in human plasma protein by a single-column high-performance liquid chromatography method with fluorescence detection
- (2009) Jean L.J.M. Scheijen et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Protection against Loss of Innate Defenses in Adulthood by Low Advanced Glycation End Products (AGE) Intake: Role of the Antiinflammatory AGE Receptor-1
- (2009) Helen Vlassara et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of Nɛ-carboxymethyl lysine
- (2009) Toshihide Kawai et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- A Novel Sartan Derivative With Very Low Angiotensin II Type 1 Receptor Affinity Protects the Kidney in Type 2 Diabetic Rats
- (2008) Yuko Izuhara et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- BENAZEPRIL, AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR, ALLEVIATES RENAL INJURY IN SPONTANEOUSLY HYPERTENSIVE RATS BY INHIBITING ADVANCED GLYCATION END-PRODUCT-MEDIATED PATHWAYS
- (2008) Xue-Ping Liu et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Impairment of the antioxidant properties of serum albumin in patients with diabetes: protective effects of metformin
- (2008) Patrice Faure et al. CLINICAL SCIENCE
- High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study
- (2008) N. Rabbani et al. DIABETOLOGIA
- Oral benfotiamine plus α-lipoic acid normalises complication-causing pathways in type 1 diabetes
- (2008) X. Du et al. DIABETOLOGIA
- Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes
- (2008) Søren S Lund et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Effects of 12-Month Valsartan Therapy on Glycation and Oxidative Stress Markers in Type 2 Diabetic Subjects With Hypertension
- (2008) Naoko Komiya et al. International Heart Journal
- The Role of Advanced Glycation End Products in Progression and Complications of Diabetes
- (2008) Su-Yen Goh et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat
- (2008) Pitchai Balakumar et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Benfotiamine reduces genomic damage in peripheral lymphocytes of hemodialysis patients
- (2008) Nicole Schupp et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Serum Levels of the Advanced Glycation End Products Nε-Carboxymethyllysine and Pentosidine Are Not Influenced by Treatment with the Angiotensin Receptor II Type 1 Blocker Irbesartan in Patients with Type 2 Diabetic Nephropathy and Hypertension
- (2008) Martin Busch et al. NEPHRON CLINICAL PRACTICE
- Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors
- (2007) A Negre-Salvayre et al. BRITISH JOURNAL OF PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started